Evidence map›Paper›PMID 21569466›Full record

ArticleBMC genetics2011

Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension.

Mogens Fenger, Allan Linneberg, Torben Jørgensen, Sten Madsbad, Karen Søbye, Jesper Eugen-Olsen, Jørgen Jeppesen

Open access · diamondAbstract read
In one paragraph

Article in BMC genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Sphingolipid signaling in kidney diseases.American journal of physiology. Renal physiology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Sphingolipid Mediators of Myocardial Pathology.Journal of lipid and atherosclerosis · 2020
    Review
  12. Sphingosine-1-phosphate signaling in blood pressure regulation.American journal of physiology. Renal physiology · 2019
    Review
  13. Review
  14. Ceramide and Regulation of Vascular Tone.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Sphingolipids in obesity and related complications.Frontiers in bioscience (Landmark edition) · 2017
    Review
  18. Article
  19. Implication of sphingosin-1-phosphate in cardiovascular regulation.Frontiers in bioscience (Landmark edition) · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mogens FengerCopenhagen University Hospital at Hvidovre, Department of Clinical Biochemistry, Genetics, and Molecular Biology, Kettegaard All 26, 2650 Hvidovre, Denmark. mogens.fenger@hvh.regionh.dk
Allan Linneberg
Torben Jørgensen
Sten Madsbad
Karen Søbye
Jesper Eugen-Olsen
Jørgen Jeppesen
Copenhagen University Hospital · DKGlostrup Hospital · DKHvidovre Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral attempts to decipher the genetics of hypertension of unknown causes have been made including large-scale genome-wide association analysis (GWA), but only a few genes have been identified. Unsolved heterogeneity of the regulation of blood pressure and the shortcomings of the prevailing monogenic approach to capture genetic effects in a polygenic condition are the main reasons for the modest results. The level of the blood pressure is the consequence of the genotypic state of the presumably vast network of genes involved in regulating the vascular tonus and hence the blood pressure. Recently it has been suggested that components of the sphingolipid metabolism pathways may be of importance in vascular physiology. The basic metabolic network of sphingolipids has been established, but the influence of genetic variations on the blood pressure is not known. In the approach presented here the impact of genetic variations in the sphingolipid metabolism is elucidated by a two-step procedure. First, the physiological heterogeneity of the blood pressure is resolved by a latent class/structural equation modelling to obtain homogenous subpopulations. Second, the genetic effects of the sphingolipid metabolism with focus on de novo synthesis of ceramide are analysed. The model does not assume a particular genetic model, but assumes that genes operate in networks.

resultsThe stratification of the study population revealed that (at least) 14 distinct subpopulations are present with different propensity to develop hypertension. Main effects of genes in the de novo synthesis of ceramides were rare (0.14% of all possible). However, epistasis was highly significant and prevalent amounting to approximately 70% of all possible two-gene interactions. The phenotypic variance explained by the ceramide synthesis network were substantial in 4 of the subpopulations amounting to more than 50% in the subpopulation in which all subjects were hypertensive. Construction of the network using the epistatic values revealed that only 17% of the interactions detected were in the direct metabolic pathway, the remaining jumping one or more intermediates.

conclusionsThis study established the components of the ceramide/sphingosine-1-phosphate rheostat as central to blood pressure regulation. The results in addition confirm that epistasis is of paramount importance and is most conspicuous in the regulation of the rheostat network. Finally, it is shown that applying a simple case-control approach with single gene association analysis is bound to fail, short of identifying a few potential genes with small effects.

Indexed as

Epistasis, GeneticBlood PressureCeramidesFemaleGenetic HeterogeneityGenetic Predisposition to DiseaseHumansHypertensionLysophospholipidsMaleModels, GeneticSphingosineCeramidesLysophospholipidsSphingosinesphingosine 1-phosphate

Identifiers

PMID21569466
PMCPMC3115901
OpenAlexW2005086748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.